當前位置：   首頁 > 需求大廳

1、P. A. Prajapati and M. M. Patel, “Formulation and in vitro evaluation of atropine sulphate viscous ocular solutions for the mydriatic and cycloplegic effect,”?International Journal of Pharmaceutical and Applied Sciences, vol. 1, no. 2, pp. 70–78, 2010.?View at Google Scholar 2、D. S. Satya, K. P. Suria, and P. P. Muthu, “Advanced approaches and evaluation of ocular drug delivery system,”?American Journal of PharmTech Research, vol. 1, no. 4, pp. 72–92, 2011.?View at Google Scholar 3、B. K. Nanjwade, D. B. Sonaje, and F. V. Manvi, “In vitro—in vivo?release of ciprofloxacin from ophthalmic formulations,”?International Journal of Pharmacy and Biotechnology, vol. 1, no. 1, pp. 23–28, 2011.?View at Google Scholar 4、Physicochemical properties and stability of nicorandil By Nagai, Hiroshi; Koizumi, Ikue; Haneda, Masatoshi; Imai, Toshikatsu; Kikuchi, Mineo; Shiba, Motoharu From Iyakuhin Kenkyu (1983), 14(6), 968-79. Language: Japanese, Database: CAPLUS 5、Sobean oil partially hydrogenated 最新德國藥典   [更多]

1、シオノケミカル株式會社サラゾスルファピリジン腸溶錠250mg「SN」の生物學的同等性に関する資料， 2、Temperature- and rigidity-mediated rapid transport of lipid nanovesicles in hydrogels 3、J Pharm Sci. 2016 Sep;105(9):2855-2863. doi: 10.1016/j.xphs.2016.03.006. Epub 2016 Apr 19. 4、https://www.sciencedirect.com/science/article/abs/pii/S0925443918300899 5、Martindale: The Complete Drug Reference, 2017, The Pharmaceutical Press. 6、http://jcmr.um.ac.ir/index.php/biology/article/view/36148 7、Benefits and harms of sugammadex versus neostigmine in reversing induced paralysis 8、Current Therapeutic Drugs Against Cerebral Vasospasm after Subarachnoid Hemorrhage: A Comprehensive Review of Basic and Clinical Studies. Curr Drug Deliv. 2017 Sep 6;14(6):843-852. doi: 10.2174/1567201813666160808100937 9、Grading Of Corneal and Conjunctival Staining in the Context of Other Dry Eye Tests 10、Blood Purif. 2018 Nov 28:1-8. doi: 10.1159/000495024. [Epub ahead of print] Risk Factors of Central Venous Catheter-Related Bloodstream Infection for Continuous Renal Replacement Therapy in Kidney Intensive Care Unit Patients. Cheng S1, Xu S1, Guo J1, He Q1, Li A1, Huang L1, Liu Z1, Li S2. 11、中國制藥信息2013年第29卷第2期：34-36 12、Chen et al. J Clin Endocrinol Metab, May 2015, 100(5). 1912-1919 13、 NUTRIENTS 2017 , 9 ( 2 ) , 138 14、Fan et al Journal of paediatrics and child health. Volume 52, Issue s2 2016 15、Association Between Vitamin D Supplementation During Pregnancy and Offspring Growth, Morbidity, and MortalityA Systematic Review and Meta-analysis 16、Effect of Higher vs Standard Dosage of Vitamin D3 Supplementation on Bone Strength and Infection in Healthy InfantsA Randomized Clinical Trial 17、Prenatal Vitamin D Supplementation to Improve Health in Offspring 18、Digoxin bioequivalence study: determination in human plasma by microparticle enzyme immunoassay. 19、文獻題目Dimeticone、刊名：Reactions Weekly, 2019, Vol.1752 (1), pp.137-137 20、Curr Neuropharmacol. 2018 Aug 27. Rothenberger A1, Roessner V2. Psychopharmacotherapy of   [更多]

求厄洛替尼或吉非替尼樣本醫(yī)院銷售數(shù)據(jù)。   [更多]

①從任務(wù)主手中獲取指定年報數(shù)量的年報文件（PDF） ②將年報中“合并利潤”、“研發(fā)投入”、“分行業(yè)分產(chǎn)品分地區(qū)收入”、“治療領(lǐng)域”、“產(chǎn)銷量”、“研發(fā)投入明細”等數(shù)據(jù)填入相應(yīng)表格中（任務(wù)主提供填寫模板） ③要求仔細認真，有責任心。 ④價格2.5元/份年報預計40份，共計100元。 ⑤若審核發(fā)現(xiàn)有錯填、漏填，以每漏填，錯填一個數(shù)據(jù)1元計量扣除賞金 ⑥以前合作做過類似項目的優(yōu)先考慮，如有感興趣的威客可聯(lián)系參與。   [更多]

Oxiconazole Nitrate Cream 美國藥典標準一份.   [更多]

求購“Clofazimine”氯法齊明《 EP9.2 》的藥典標準一份.   [更多]

維生素A棕櫚酸酯信息   [更多]

根據(jù)已知企業(yè)名稱（寫法不規(guī)范） 去CFDA http://app1.sfda.gov.cn/datasearchcnda/face3/base.jsp?tableId=25&tableName=TABLE25&title=%B9%FA%B2%FA%D2%A9%C6%B7&bcId=152904713761213296322795806604 或 藥智數(shù)據(jù)https://db.yaozh.com/pijian 查找對應(yīng)的規(guī)范企業(yè)名稱 無法確認的需備注好原因 規(guī)范數(shù)據(jù)按照0.05元/條（10000條500元） 備注數(shù)據(jù)按照0.01元/條（10000條100元） 準確率要求98%。   [更多]

1.Myopia Control with Bifocal Contact Lenses:?A Randomized Clinical Trial 2.The Role of Atropine Eye Drops in Myopia Control 4. Myopia Control: A Review 7. Efficacy of 1%?atropine?eye drops in retarding progressive axial myopia in Indian eyes 8.Atropine?0.01% Eyedrops Significantly Reduce the Progression of Childhood Myopia 9.Current approaches to myopia control 10.Atropine?for the Prevention of Progression in Myopia - Data, Side Effects, Practical Guidelines 13. Atropine?0.01% Eyedrops Significantly Reduce the Progression of Childhood Myopia. 18. The treatment of myopia with?atropine?and bifocals. A long-term prospective study 19. Inhibitory effects of apomorphine and?atropine?and their combination on myopia in chicks 20. The penetration and distribution of topical?atropine?in animal ocular tissues. 21. Treatment outcomes of?myopic?anisometropia with 1%?atropine: a pilot study 23. Does?atropine?use increase intraocular pressure in?myopic?children? 24. Atropine?use for the prevention of myopia progression 25. Allergic reactions to?atropine?eye drops for retardation of progressive myopia in children. 29. Maximum?atropine?dose without clinical signs or symptoms. 31. Atropine?and bifocals can slow the progression of myopia in children. 33. Prevention of myopia onset with 0.025%?atropine?in premyopic children 35. The long-term results of using low-concentration?atropine?eye drops for controlling myopia progression in schoolchildren. 37. Prevention of myopia progression with 0.05%?atropine?solution.   [更多]

求購“Metformin hydrochloride”《 EP9.1 》《 EP9.2 》的藥典標準一份，Metformin hydrochloride Tablets”《 USP42 》的藥典標準一份.   [更多]